Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hospices Civils de Lyon
Constitution of a prospective cohort of 128 patients with 8 different groups of patients. This protocol is designed to evaluate a new tool for detecting the diversity of the repertoire T and B in patients with hematological disease. This in vitro diagnostic device is consisting of molecular biology kits Human ImmunTraCkeR® and Human Immun'IgH® and the analysis tool NDL®
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
18 Years and older
Subjects with a diagnosis of large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, MALT, marginal zone, Waldenstrom's disease, chronic lymphocytic leukemia, T-cell lymphoma, anaplastic, cytotoxic or peripheral unspecified angioimmunoblastic.
Have signed an informed consent for participation in the study and preservation of blood samples for biomedical research.
Accept to appear in consultation biological samples at the sampling points corresponding to its group.
The benefits of social security.
You may not be if
Subjects with a diagnosis of Hodgkin disease
Subjects with a diagnosis of T-prolymphocytic leukemia
Subjects with a diagnosis of Burkitt's lymphoma
Subjects with a diagnosis of lymphoblastic lymphoma
Subjects who had prior-treatment for hematological disease
